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Abstract The production of leukotriene A4 (LTA4)-derived 
metabolites, analysed by RP-HPLC, was studied in purified 
bovine polymorphonuclear leukocyte (PMNL) preparations and 
in PMNL-platelet coincubations after challenge with the calcium 
ionophore A23187. The results obtained show that in bovine 
PMNL LTB4 represents the main LTA4 metabolite. When 
washed platelets were added to PMNL, LTC4 was the main 
enzymatic metabolite observed, indicating a substantial transfer 
of PMNL-derived LTA4 to platelets. The synthesis of LTC4 was 
accompanied by a significant decrease in LTB4, suggesting that a 
quota of the LTB4 synthesized in PMNL preparations is the 
result of transcellular metabolism of released LTA4 by 
neighbouring PMNL. Reduction of PMNL-PMNL interactions 
through dilution of cell incubates allowed us to estimate that 
most of the leukotriene A4 synthesized by PMNL is indeed 
released from the cell. LTA4, and not LTB4, represents the main 
5-1ipoxygenase metabolite released by bovine PMNL. 
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1. Introduction 
Arachidonic acid oxidation catalyzed by 5-1ipoxygenase (5- 
LO; EC 1.13.11.34) activity leads to the formation of potent, 
biologically active molecules uch as leukotriene B4 (LTB4), 
and cysteinyl leukotrienes, namely leukotriene C4 (LTC4), leu- 
kotriene D4 (LTD4), and leukotriene E4 (LTE4)[1,2]. While a 
great deal of evidence from basic biochemical studies has fo- 
cused on cells that possess 5-LO enzyme, it is now clear that 
the formation of leukotrienes i not strictly limited to those 
cells that have these primary oxidative enzymes. Recent ex- 
periments have shown that the chemically reactive intermedi- 
ate leukotriene A4 (LTA4)[3] can be transferred from one cell 
to another. Conversion of LTA4 to LTB4 and LTCI has been 
shown in cells that do not possess 5-LO activity such as red 
blood cells [4], platelets [5], endothelial cells [6,7] and smooth 
muscle cells [8]. 
Recent studies using organ systems perfused with PMNL 
[9-11] have indicated the pathophysiological relevance of the 
transcellular metabolism of LTA4, in particular when tight 
cell-cell interactions occur, such as during adhesion and dia- 
pedesis of PMNL through the microvascular endothelium. 
Polymorphonuclear leukocytes (PMNL) possess large 
amounts of 5-LO, the enzyme catalyzing the sequential con- 
version of arachidonic acid to 5-hydroperoxyeicosatetraenoic 
acid (5-HpETE) and LTA4 [12]. Upon cell activation, non- 
enzymatic LTA4 breakdown products, such as A6-trans-LTB4 
isomers and 5,6-diHETE isomers [13-15] are found in cell 
incubation media, suggesting the extracellular elease of 
LTA4. 
Although a few studies have carefully addressed the trans- 
cellular metabolism of LTA4 in PMNL-platelet coincubations 
[5,16], as well as the amounts of LTA4 released upon calcium 
ionophore A23187 challenge of human PMNL [17], no quan- 
titative data are available that would relate the amounts of 
LTA4 released from PMNL alone to those of LTC4 synthe- 
sized by transcellular metabolism in PMNL-platelet coincuba- 
tions. 
In the present paper we studied the transcellular metabo- 
lism of LTA4 in bovine blood cells, using purified polymor- 
phonuclear leukocytes, washed platelets and coincubations of 
PMNL platelets. The effect of cell concentration on the quan- 
titative profile of enzymatic (namely LTB4) versus non-enzy- 
matic LTA4 metabolites produced after challenge with the 
calcium ionophore A23187 was also studied. 
The results provide evidence that transcellular metabolism 
of LTA4 takes place in bovine PMNL preparations as well as 
in PMNL-platelet coincubations, and that intact LTA4 repre- 
sents the main 5-LO metabolite released by bovine PMNL. 
2. Materials and methods 
2.1. Chemicals and reagents 
All chemicals used were reagent grade and obtained from commer- 
cial sources. Eicosanoids were purchased from Cayman Chemical Co. 
(Ann Arbor, MI, USA). HPLC-grade solvents were obtained from 
Merck (Darmstadt, Germany). Ficoll was from Pharmacia (Uppsala, 
Sweden). Type I 'plus' water was obtained using a MilliQ Plus water 
purifier (Millipore, Molsheim, France), fed with double-distilled 
water. 
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Abbreviations." LTA4, leukotriene AA; LTB4, leukotriene B4; LTC,~, 
leukotriene C4; PMNL, polymorphonuclear leukocytes; 5-LO, 5- 
lipoxygenase; PBS =, PBS without Ca 2+ and Mg 2+ ; PRP, platelet-rich 
plasma; A6-trans-LTB4 isomers, 5(S),12(R)-dihydroxy-6,8,10-trans-14- 
cis-eicosatetraenoic acid and 5(S),12(S)-dihydroxy-6,8,10-trans-14-cis- 
eicosatetraenoic acid; 5,12-diHETE, 5(S),12(S)-dihydroxy-6,10-trans- 
8,14-cis-eicosatetraenoic acid; 5,6-diHETE isomers, 5(S),6(S)-dihy- 
droxy-7,9-trans-ll,14-cis-eicosatetraenoic acid and 5(S),6(R)-dihy- 
droxy-7,9-trans-11,14-cis-eicosatetraenoic cid 
2.2. Preparation of bovine platelets and polymorphonuclear leukocytes 
Bovine polymorphonuclear leukocytes and platelets were prepared 
according to Hansbrough et al. [18] and Henricks et al. [19], with 
modifications. Briefly, blood (7 vols.) was collected at time of slaugh- 
ter in 1 vol. ACD (citric acid-H20, 41 mM; Na + citrate.2H20, 100 
mM; glucose, 136 mM) and carefully mixed. After centrifugation for 
20 min at room temperature and 380xg, platelet-rich plasma (PRP) 
was removed and reacidified with 1:10 (v/v) ACD. The residual blood 
was further centrifuged for 10 min at room temperature and 1300 ×g, 
and the pellet subjected to erythrocyte lysis by gentle resuspension in 
1 vol. of a 0.2% (w/v) NaC1 solution and further dilution with 1 vol. 
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of a balancing solution (1.6% NaC1, w/v; 0.2% sucrose, w/v) at +4°C. 
Mononuclear cells were then separated by centrifugation (30 min at 
room temperature and 400xg) on Ficoll cushions (density 1.077 g 
m1-1) and the pellet, containing neutrophils (75-95%) and eosinophils 
(5-25%), was washed twice in PBS without Ca 2+ and Mg 2+ (PBS=), 
resuspended at a final concentration of approx. 30x 10 6 cells m1-1 
and kept on ice until use. 
PRP was centrifuged for 15 min at room temperature and 1000xg, 
and platelets resuspended with 5 ml of washing buffer (citric acid. 
H20, 36 raM; glucose.H20, 5 mM; KC1, 5 mM; CaCI2, 2 mM; 
MgC12"6H20, 1 mM; NaC1, 103 mM; pH 6.5) containing 0.4% (w/ 
v) BSA and prostaglandin E1 (final concentration 100 nM), according 
to Patscheke [20]. Platelets were further centrifuged for 15 min at 
room temperature and 400 xg, and finally resuspended in PBS =. 
Platelets and PMNL were counted using a modified Neubauer 
chamber and viability, as assessed by trypan blue dye exclusion, 
amounted to ->95%. 
2.3. Cell incubations 
PMNL (5X10 6 cells m1-1 for coincubations or 1-20X106 cells 
m1-1 for dilution experiments) and/or platelets (2× l0 s cells m1-1) 
were supplied with Ca 2+ (2 mM) and Mg 2+ (0.5 mM) and, following 
pre-incubation at 37°C for 5 min, the calcium ionophore A23187 
(Calbiochem, La Jolla, CA, USA; 5 ktM) was added to trigger eico- 
sanoid metabolism. 
Stimulation was terminated after 10 min with 2 vols. of ice-cold 
methanol containing the HPLC internal standard prostaglandin Be 
(PGB2, 25 ng) and samples tored at -20°C until RP-HPLC analysis. 
2.4. Analysis of leukotriene A4-derived metabolites 
Samples were diluted with water to a final methanol concentration 
lower than 20% and extraction was quickly carried out using a solid 
phase cartridge (Supelclean LC-18, Supelco, Bellafonte, PA); the re- 
tained material was eluted using 90% aqueous MeOH. After evapora- 
tion, the dried extract was reconstituted in 600 ~tl of HPLC mobile 
phase A (methanol/acetonitrile/water/acetic id 10:10:80:0.02, v/v, 
pH 5.5 with ammonium hydroxide), and injected into an HPLC gra- 
dient pump system (model 126, Beckman Analytical, Palo Alto, CA, 
USA) connected to a diode-array UV detector (model 168, Beckman 
Analytical), using a microprocessor-controlled auto sampler (Jasco 
851-AS, Tokyo, Japan), with the sample kept at 4°C. UV absorbance 
was monitored at 280 nm, and full UV spectra (210-340 nm) acquired 
at a rate of 0.5 Hz. 
A multilinear gradient from mobile phase A to mobile phase B 
(methanol/acetonitrile 50:50) at a flow rate of 1 ml min -1, was used 
to elute a 4x250 mm column (RP-18 endcapped Lichrospher, 5 I.tm, 
Merck). Solvent B was increased to 35% over 6 min, to 65% over 25 
min and to 100%o ver 3 min. This method allows separation of LTB4 
from 5,12-diHETE as well as from non-enzymatic LTA4 metabolites. 
Positive identification of enzymatic and non-enzymatic LTA4 me- 
tabolites was made through UV spectral analysis of chromatographic 
peaks eluting at characteristic retention times. Quantitation was car- 
ried out on positively identified peaks only, using their HPLC peak 
areas relative to that of PGB2 at 280 nm, and calculated from the 
responses of standard compounds. The ratio (enzymatic LTA4 meta- 
bolites)/(non enzymatic LTA4 metabolites) in PMNL preparations at
different cell density, was calculated using the amount of LTB4 di- 
vided by the amount of Ar-trans-LTB4 isomers+5,6-diHETE isomers. 
LTAa metabolites in PMNL preparations and PMNL-platelet co- 
incubations were defined as [enzymatic LTA4 metabolites (namely 
LTB4+LTC4)]+[non-enzymatic LTA4 metabolites (namely Ar-trans - 
LTB4 isomers+5,6-diHETE isomers)]. 
2.5. Data presentation and statistics 
The results were expressed as means + standard error of the mean 
(S.E.M.) of 4-5 different cell preparations. 
Difference analyses between PMNL and PMNL-platelet coincuba- 
tions were performed by Student's t-test. Comparison of enzymatic 
and non-enzymatic LTA4 metabolites in different cell concentration 
groups were carried out by analysis of variance (ANOVA) and post 
hoc analysis performed with the Tukey-Kramer HSD test. ANOVA 
and linear regression analysis were used to examine the relationship 
between the cell concentration and the ratio (enzymatic LTA4 meta- 
bolites)/(non-enzymatic LTA4 metabolites). 
The level of significance considered was < 5%. 
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Fig. 1. LTA4 metabolites synthesized by bovine PMNL and PMNL- 
platelet coincubations. UV absorbance profile at 280 nm from the 
RP-HPLC of bovine PMNL (5×10 e cells m1-1) (A) and PMNL- 
platelet coincubations (ratio 1:40) (B) after challenge with the Ca 2+ 
ionophore A23187 (5 /.tM, 10 min, 37°C). Peaks are labeled as fol- 
lows: a, LTC4; b, PGB2 (HPLC internal standard); c, A6-trans- 
LTB4 isomers; d, LTB4; e, 5,12-diHETE; f, 5,6-diHETE isomers. 
Inset: UV spectrum of peak a, obtained on-line with the diode-ar- 
ray UV detector. 
3. Results 
3.1. Bovine PMNL-plate let  coincubations 
Challenge of PMNL preparat ion (5× 106 cells m1-1) with 
the calcium ionophore A23187 (5 ~tM, 10 min at 37°C), re- 
sulted in the product ion of LTB4 (21.9+ 3.1 pmol/106 cells) 
and of non-enzymatic LTA4 metabolites (A6-trans-LTB4 iso- 
mers+5,6-diHETE isomers, 17.4+2.6 pmol/106 cells) while 
neither LTC4 nor  ¢0-oxidized LTB4 metabolites [21] were de- 
tectable. No LTA4 metabolites were observed in the absence 
of calcium ionophore A23187 challenge. 
Addit ion of washed, homologous platelets in a ratio of 40:1 
with PMNL resulted in the appearance of substantial amounts 
of LTC4 (18.1 +4.4 pmol/106 cells), representing the main 
LTA4-derived metabolite (Fig. 1). A statistically significant 
decrease in both LTB4 and non-enzymatic LTA4 metabolites 
was also observed, while the total amount  of LTA4 metabo- 
lites remained unchanged (Fig. 2). 
5,12-diHETE, a metabolite arising from the sequential ac- 
t ion of the 5- and 12-1ipoxygenase on arachidonic acid [22], 
was detected in PMNL incubations (4.9 + 2.2 pmol/106 cells), 
according to the presence of 12-1ipoxygenase in bovine leuko- 
cytes [18]. Addit ion of homologous platelets caused a signifi- 
cant increase in this double oxygenation metabolite (22.7 + 5.7 
pmol/106 PMNL) ,  consistent with the presence of the platelet 
12-1ipoxygenase. 
3.2. Bovine PMNL dilution experiments 
Challenge of bovine PMNL preparations (20)<106 cells 
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Fig. 2. LTA4 metabolites synthesized by bovine PMNL and PMNL- 
platelet coincubations. Amounts of LTA4 metabolites (expressed as 
pmol/106 cells) synthesized by bovine PMNL (5x106 cells ml --1) 
(cross-hatched bars) and PMNL-platelet coincubations (ratio 1:40) 
(solid bars) after challenge with the Ca 2+ ionophore A23187 (5 gM, 
10 min, 37°C). Values are means + S.E.M. of 5 different PMNL pre- 
parations, n.d., not detectable. Differences between the groups, as- 
sessed by Student's t-test, are indicated: **p<0.01, ***p<0.001 
from the PMNL group. 
m1-1) with the calcium ionophore A23187 (5 gM, 10 min, 
37°C) resulted in the production of LTB4 (17.3 + 0.5 pmol/ 
l06 cells) and of non-enzymatic LTA4 metabolites. 
Decreasing cell concentration from 20× 106 to 10 ~ cells 
m1-1 resulted in a significant increase in non-enzymatic 
LTA4 metabolites (from 6.6 + 1.1 to 24.9 + 2.2 pmol/106 cells, 
p < 0.001 by Tukey-Kramer HSD test). 
The normalized percentile composition of enzymatic and 
non-enzymatic LTA4 metabolites over the total LTA4-derived 
metabolites showed a progressive increase of non-enzymatic 
LTAa metabolites representing 27% at 20 x 106 cells m1-1 and 
59.6% at 1 X 106 cells m1-1 (Fig. 3). 
A statistically significant linear correlation (r=0.783, 
p<0.001) between the concentration of PMNL m1-1 and 
the ratio (enzymatic LTA4 metabolites)/(non-enzymatic 
LTA4 metabolites) was observed (Fig. 4). 
4. Discussion 
The importance of transcellular metabolism of leukotriene 
A4 with regard to the final profile of 5-1ipoxygenase metabo- 
lites observed in biological systems has recently been sup- 
ported by an increasing body of evidence. The cellular envir- 
onment may strongly influence the qualitative as well as 
quantitative profile of LTA4-derived metabolites generated 
upon activation of polymorphonuclear leukocytes. Endothe- 
lial cells, smooth muscle cells and platelets have been shown 
to possess LTC4-synthase (EC 2.5.1.37) and are able to 
synthesize LTC4 using exogenous LTAa as well as PMNL- 
derived LTA4. This process may lead to a pronounced shift 
from the production of a chemotactic lipid mediator, such as 
LTBa, to cysteinyl leukotrienes, which cause oedema nd va- 
soconstriction [23,24]. The overall potential for LTA4 transfer 
from PMNL (donor cell) to acceptor cells [25], has usually 
been quantitated using the amounts of non-enzymatic LTA4 
metabolites in purified PMNL incubations [9]. Nevertheless, 
given the capacity of PMNL to take up actively LTA4 from 
the extracellular milieu and convert it to LTB4 [26], this esti- 
mate could represent an undervaluation of the amount of 
LTA4 indeed leaving the cell for the extracellular environ- 
ment. In a previous work by Fiore and Serhan [17], increased 
amounts of LTA4-derived products were shown in human 
PMNL after A23187 challenge, by the trapping of LTA4 out- 
side of PMNL with liposomes. These observations suggested 
that the amount of LTAa released by human PMNL could 
indeed be greater than that estimated using non-enzymatic 
LTA4 metabolites in purified PMNL preparation. 
Bovine PMNL represent a very useful model for the study 
of LTA4 transcellular metabolism for different reasons: 
(i) Bovine PMNL do not synthesize LTC4, in spite of the 
presence of eosinophils [18,19,27]; the observed formation of 
LTC4 in PMNL-platelet coincubations i  therefore totally de- 
pendent on the transfer of LTA4 from PMNL to thrombo- 
cytes 
(ii) Bovine PMNL do not show significant o~-oxidative me- 
tabolism of LTB4; this simplifies the evaluation of PMNL 
enzymatic metabolites. In human PMNL o~-oxidized eriva- 
tives of LTBa (20-hydroxy- and 20-carboxy-LTB4)[21] repre- 
sent the predominant enzymatic metabolites and their forma- 
tion is mainly carried out by neighbouring PMNL, taking up 
LTB4 synthesized by other PMNL [28,29]. Diluting cell con- 
centration would result, in the case of human PMNL, in sub- 
stantial changes of the relative amounts of LTB4 and its co- 
oxidized metabolites. 
The results obtained with this study show that bovine plate- 
lets, as previously shown for human platelets [5,16], are able 
to take up efficiently PMNL-derived LTA4 and metabolize it
to LTC4, representing the main LTA4-derived metabolite in 
PMNL-platelet coincubations. Accordingly, non-enzymatic 
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Fig. 3. Normalized percent composition of LTA4 metabolites 
synthesized by bovine PMNL. Relative amounts of enzymatic and 
non-enzymatic LTA4 metabolites ynthesized by bovine PMNL at 
different concentrations, after challenge with the Ca 2+ ionophore 
A23187 (5 ~tM, 10 min, 37°C). Data are expressed as % of total (en- 
zymatic+non-enzymatic) LTA4 metabolites. Values are means 
+ S.E.M. of 4 different PMNL preparations. 
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Fig. 4. Correlation between the ratio enzymatic/non-enzymatic 
LTA4 metabolites and cell concentration i bovine PMNL prepara- 
tions. Relationship between the ratio (enzymatic LTA4 metabolites)/ 
(non-enzymatic LTA4 metabolites) and the concentration of bovine 
PMNL challenged with the Ca 2+ ionophore A23187 (5 gM, 10 min, 
37°C). Values are means_+S.E.M, of 4 different PMNL prep- 
arations, r = 0.783, p< 0.0001 
LTA4 metabolites (namely A6-trans-LTB4 isomers and 5,6-di- 
HETE isomers) decreased by 70% compared to PMNL alone, 
indicating that the presence of platelets prevented the non- 
enzymatic decay of LTA4 released by PMNL. Addition of 
platelets to PMNL preparations also resulted in a statistically 
significant decrease of LTB4. It is important to note that the 
decrease in non-enzymatic LTA4 metabolites, together with 
the decrease in LTB4, quantitatively accounted for the 
amounts of LTC4 detected. The decrease of LTB4 observed, 
suggested that over 25% of LTB4 synthesized in PMNL prep- 
arations at a concentration f 5 × 106 PMNL m1-1 arises from 
the release of intact LTA4 and further metabolism to LTBa by 
neighbouring PMNL. In order to test this hypothesis, reduc- 
tion of cell concentration, resulting in increased average dis- 
tance between cells, has been used as a tool to limit the 
amount of further enzymatic metabolism of released LTA4 
by neighbouring PMNL. Decrease of cell concentration i
PMNL preparations challenged with the calcium ionophore 
A23187 resulted in increased amounts of non-enzymatic LTA4 
metabolites with respect to enzymatic LTA4 metabolites 
(LTBa). The decrease of the ratio LTBj(non-enzymatic 
LTA4 metabolites) linearly correlated with the decreased num- 
ber of PMNL per ml of incubation medium, indicative of a 
diminished contribution of neighbouring PMNL to the final 
amounts of LTB4 observed. 
Albumin is known to stabilize LTA4, increasing its half-life 
in buffered solution at pH 7.4 from less than 10 s to several 
minutes [28,17]. Nevertheless, in the experiments on PMNL 
dilution, we were took advantage of the very short half-life of 
intact LTA4 to trap the LTA4 released from the cell, by non- 
enzymatic hydrolysis to A%trans-LTB4 and 5,6-diHETE iso- 
mers. Therefore, albumin was not used throughout these ex- 
periments because it was anticipated that increasing the half- 
life of the LTAa released would result in a greater chance of 
being taken up again and enzymatically metabolized by sur- 
rounding cells. 
In PMNL-platelet coincubation, a very efficient transfer of 
PMNL-derived LTA4 to platelets in the absence of albumin 
was observed, supporting the hypothesis that cell-cell contact 
may play a pivotal role in the efficient transfer of LTA4 re- 
sulting in the formation of cysteinyl leukotrienes. In fact, in- 
hibition of LTC4 formation arising from the interaction of 
human PMNL and glomerular endothelial cells, by antibodies 
against CD18 and L-selectin, has recently been reported [30]. 
It has previously been shown that challenge of PMNL while 
perfusing isolated lung or heart of the rabbit resulted in a shift 
from LTB4, observed after challenge of isolated PMNL, to 
cysteinyl eukotrienes, representing the main 5-LO product 
observed in the perfusion media [9-11]. The data obtained 
in this work support the hypothesis that a diversion from 
LTA4 hydrolase to LTC4 synthase metabolites could indeed 
take place when PMNL are activated in the context of tight 
interactions with cells (i.e. platelets, endothelial cells, smooth 
muscle cells) possessing the LTC4 synthase nzyme. 
In addition, the results obtained clearly show that intact 
LTA4, and not LTBa, represents he main leukotriene r leased 
upon activation by bovine PMNL. Further studies are in pro- 
gress to test whether this observation may be also relevant for 
human PMNL. 
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